Pimozide treatment of a male case with de Clerambault's syndrome and schizophrenia.
Effective treatment with pimozide of a male patient with secondary de Clérambault's syndrome (DCS) and schizophrenia is reported. There was no evidence of relapse at 24-month follow-up. Pimozide is suggested to be the drug of choice in DCS and may be in other disorders in which symptoms of erotomania are prominent. The unique anti-erotomanic activity of pimozide may be due to its calcium channel antagonist activity, a property which is not shared by the other antipsychotic drugs.